Psoriasis is a common, chronic, immune-mediated skin and joint disease that significantly impacts patients' physical, emotional, and psychosocial well-being. It occurs worldwide, with varying prevalence among ethnic groups. Genetic factors play a major role, but environmental triggers like infections also contribute. Psoriasis typically presents as chronic, symmetrical, erythematous, and scaly plaques, though it can manifest in various forms, including plaque, guttate, inverse, erythrodermic, pustular, and palmoplantar types. Nail involvement and psoriatic arthritis are also common. The disease can occur at any age, with two peaks: one in early adulthood (15–20 years) and another in middle age (55–60 years). Psoriasis has a complex genetic basis, with multiple susceptibility loci identified, including PSORS1 on chromosome 6p21 and others on various chromosomes. However, the exact genetic mechanisms remain to be fully determined. Psoriasis significantly affects quality of life, with patients reporting reduced well-being, stigma, and psychological distress. It is associated with depression and suicidal ideation in some cases. Psychological factors, such as stress and anxiety, can exacerbate or trigger psoriasis. Quality of life assessments are crucial in evaluating treatment effectiveness, as they reflect both physical and psychological aspects of the disease. Various instruments are used to measure quality of life in psoriasis, including the Salford Psoriasis Index (SPI), which assesses physical severity, psychosocial disability, and treatment history. These tools help in understanding the impact of psoriasis on patients' daily lives and guide treatment decisions. Despite the availability of these tools, further research is needed to refine their use and better define clinically meaningful changes in quality of life.Psoriasis is a common, chronic, immune-mediated skin and joint disease that significantly impacts patients' physical, emotional, and psychosocial well-being. It occurs worldwide, with varying prevalence among ethnic groups. Genetic factors play a major role, but environmental triggers like infections also contribute. Psoriasis typically presents as chronic, symmetrical, erythematous, and scaly plaques, though it can manifest in various forms, including plaque, guttate, inverse, erythrodermic, pustular, and palmoplantar types. Nail involvement and psoriatic arthritis are also common. The disease can occur at any age, with two peaks: one in early adulthood (15–20 years) and another in middle age (55–60 years). Psoriasis has a complex genetic basis, with multiple susceptibility loci identified, including PSORS1 on chromosome 6p21 and others on various chromosomes. However, the exact genetic mechanisms remain to be fully determined. Psoriasis significantly affects quality of life, with patients reporting reduced well-being, stigma, and psychological distress. It is associated with depression and suicidal ideation in some cases. Psychological factors, such as stress and anxiety, can exacerbate or trigger psoriasis. Quality of life assessments are crucial in evaluating treatment effectiveness, as they reflect both physical and psychological aspects of the disease. Various instruments are used to measure quality of life in psoriasis, including the Salford Psoriasis Index (SPI), which assesses physical severity, psychosocial disability, and treatment history. These tools help in understanding the impact of psoriasis on patients' daily lives and guide treatment decisions. Despite the availability of these tools, further research is needed to refine their use and better define clinically meaningful changes in quality of life.